These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 11867007)
1. An Overview of Epstein-Barr Virus: from Discovery to Future Directions for Treatment and Prevention. Andersson J Herpes; 2000 Oct; 7(3):76-82. PubMed ID: 11867007 [TBL] [Abstract][Full Text] [Related]
3. Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide. Okugawa K; Itoh T; Kawashima I; Takesako K; Mazda O; Nukaya I; Yano Y; Yamamoto Y; Yamagishi H; Ueda Y Oncol Rep; 2004 Oct; 12(4):725-31. PubMed ID: 15375491 [TBL] [Abstract][Full Text] [Related]
4. Establishment of cytotoxic T lymphocytes specific for autologous Epstein-Barr virus in HIV-infected patients: the feasibility study of EBV-specific immunotherapy for patients with EBV-associated lymphoma. Hansasuta P; Incomserb P; Buranapraditkun S; Bhattarakosol P J Med Assoc Thai; 2004 Sep; 87 Suppl 2():S146-51. PubMed ID: 16083179 [TBL] [Abstract][Full Text] [Related]
5. Epstein-Barr Virus (EBV): infection, propagation, quantitation, and storage. Lan K; Verma SC; Murakami M; Bajaj B; Robertson ES Curr Protoc Microbiol; 2007 Aug; Chapter 14():Unit 14E.2. PubMed ID: 18770612 [TBL] [Abstract][Full Text] [Related]
9. Epstein-Barr virus-encoded dUTPase modulates immune function and induces sickness behavior in mice. Padgett DA; Hotchkiss AK; Pyter LM; Nelson RJ; Yang E; Yeh PE; Litsky M; Williams M; Glaser R J Med Virol; 2004 Nov; 74(3):442-8. PubMed ID: 15368518 [TBL] [Abstract][Full Text] [Related]
10. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. Comoli P; Pedrazzoli P; Maccario R; Basso S; Carminati O; Labirio M; Schiavo R; Secondino S; Frasson C; Perotti C; Moroni M; Locatelli F; Siena S J Clin Oncol; 2005 Dec; 23(35):8942-9. PubMed ID: 16204009 [TBL] [Abstract][Full Text] [Related]
11. Adoptive immunotherapy with allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes for recurrent, EBV-positive Hodgkin disease. Lucas KG; Salzman D; Garcia A; Sun Q Cancer; 2004 May; 100(9):1892-901. PubMed ID: 15112270 [TBL] [Abstract][Full Text] [Related]